Investor Presentation January 2022
CooperSurgical
Extensive office and surgical platform
Business Highlights
Produce over 600 clinically-relevant medical
devices used by women's health care providers
in gynecology and obstetrics
Recently closed Generate Life Science
acquisition (12/17/21)
Expands CSI Labor & Delivery
Adds a well-established cord blood and
cord tissue storage platform
Leverages CSI's highly-respected
clinical/professional relationships to
cross-sell and advance education
Solid recurring revenue stream
Industry Highlights
Medical Device Drivers:
-
Shifting to minimally invasive procedures
Reimbursement is designed to drive
procedures to the office
Health systems are looking for
partnership relationship with vendors
Cord Blood and Cord Tissue Storage Drivers:
Advancing stem cell research & therapies
increase potential value of storage
Cord blood is standard of care alternative
to bone marrow transplants for blood
disorders¹
Regenerative Medicine potential
applications rapidly emerging (lung
disease, sports injury, etc.) with 1k+
ongoing clinical studies²
Gynecology Obstetrics
Office-based
providers
Labor &
Delivery
Operating
room
endosee ADVANCE
Paragard
intrauterine copper contraceptive
cbr
Cord deed
INSORB Skin Stapler
Absorbable | Subcuticular
RUMI II SYSTEM
CooperCompanies
1.
2.
Chao, N. Selection of an umbilical cord blood graft for hematopoietic cell transplantation. In: UpToDate. Negrin,R (Ed), UpToDate, Waltham, MA.
https://www.statista.com/statistics/1088694/regenerative-medicine-clinical-trials-by-phase-and-therapy/Accessed Nov 10, 2021
17View entire presentation